Hengrui Pharma(SH:600276) Xin Lang Ji Jin·2025-07-09 05:53Group 1 - The Shanghai Composite Index returned to 3500 points, with the pharmaceutical and medical sectors experiencing significant gains, particularly the pharmaceutical sector which saw a net inflow of nearly 4.1 billion yuan [1] - The leading pharmaceutical ETF (562050) surged by 2% in the afternoon, currently up 1.42%, with a trading volume exceeding 16 million yuan [1] - Major innovative drug companies like Heng Rui Pharma and Bei Da Pharma saw substantial stock price increases, with Heng Rui Pharma rising over 7% and Bei Da Pharma over 3% [2][3] Group 2 - Heng Rui Pharma announced that its subsidiary received clinical trial approval for SHR-2173 injection and HRS-9821 inhalation powder [3] - As of 2024, China has over 4000 innovative drugs in development, accounting for approximately 30% of the global total [3] - The revenue of Chinese innovative drug companies is expected to grow further in the second half of 2025, with more companies likely to achieve profitability [4] Group 3 - The pharmaceutical ETF (562050) is the first in China to track the CSI Pharmaceutical Index, focusing on innovative drugs and traditional Chinese medicine, while excluding medical and CXO sectors [4] - The largest medical ETF in A-shares (512170) focuses on medical devices and services, with a high correlation to AI healthcare, covering six leading CXO stocks [4]